Bp Plc increased its position in Hologic, Inc. (NASDAQ:HOLX) by 240.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 119,000 shares of the medical equipment provider’s stock after buying an additional 84,000 shares during the period. Bp Plc’s holdings in Hologic were worth $5,399,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the company. TrimTabs Asset Management LLC boosted its position in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC bought a new position in Hologic during the first quarter worth about $201,000. Miles Capital Inc. bought a new position in Hologic during the first quarter worth about $206,000. Beck Mack & Oliver LLC bought a new position in Hologic during the second quarter worth about $209,000. Finally, Stratos Wealth Partners LTD. bought a new position in Hologic during the first quarter worth about $210,000. Institutional investors and hedge funds own 94.46% of the company’s stock.
Hologic, Inc. (HOLX) opened at 39.03 on Tuesday. The firm has a market capitalization of $10.95 billion, a PE ratio of 14.54 and a beta of 0.90. The firm has a 50-day moving average of $45.06 and a 200 day moving average of $42.98. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted $0.51 earnings per share. Equities research analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current year.
WARNING: This story was first posted by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/hologic-inc-holx-shares-bought-by-bp-plc/1408533.html.
HOLX has been the subject of a number of research analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $51.00 price objective on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, BTIG Research reiterated a “buy” rating and set a $47.00 price objective on shares of Hologic in a research report on Sunday, May 14th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $48.64.
In other Hologic news, Director Lawrence M. Levy sold 9,837 shares of Hologic stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $45.34, for a total transaction of $446,009.58. Following the transaction, the director now directly owns 40,577 shares of the company’s stock, valued at $1,839,761.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of Hologic stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now directly owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. Insiders have sold 70,464 shares of company stock worth $3,078,921 over the last three months. Insiders own 0.79% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.